ABC Arbitrage SA bought a new stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 34,710 shares of the company's stock, valued at approximately $500,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new position in HUTCHMED during the 3rd quarter valued at $35,000. Blue Trust Inc. increased its holdings in shares of HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock valued at $69,000 after purchasing an additional 3,057 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in HUTCHMED by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock worth $117,000 after purchasing an additional 2,321 shares in the last quarter. Summit Trail Advisors LLC boosted its position in shares of HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after purchasing an additional 1,647 shares in the last quarter. Finally, Crossmark Global Holdings Inc. bought a new stake in shares of HUTCHMED during the 3rd quarter worth $328,000. 8.82% of the stock is owned by institutional investors and hedge funds.
HUTCHMED Stock Up 8.1 %
Shares of HUTCHMED stock traded up $1.11 during trading on Wednesday, reaching $14.83. The company's stock had a trading volume of 142,422 shares, compared to its average volume of 85,841. HUTCHMED has a one year low of $12.84 and a one year high of $21.92. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The business's fifty day moving average price is $14.32 and its 200-day moving average price is $16.95.
Analysts Set New Price Targets
Separately, StockNews.com downgraded HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Check Out Our Latest Stock Report on HCM
HUTCHMED Company Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
